Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vogelzang, N. J.
Right arrow Articles by Green, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogelzang, N. J.
Right arrow Articles by Green, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:597-600, 1999
© 1999 European Society for Medical Oncology

brief-report

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234

N. J. Vogelzang1,, J. E. Herndon, II2, A. Miller3, G. Strauss4, G. Clamon5, F. M. Stewart6, J. Aisner7, A. Lyss8, M. R. Cooper9, Y. Suzuki10 and M. R. Green11

1University of Chicago, Department of Medicine, Section of Hematology/Oncology Chicago, IL, USA
2CALGB Statistical Center, Duke University Medical Center Durham, NC, USA
3University of Tennessee Memphis, TN, USA
4Dana Farber Cancer Institute Boston, MA, USA
5University of Iowa, University of Iowa Iowa City, IA, USA
6University of Massachusetts Medical Center Worcester, MA, USA
7University of Maryland Baltimore, MD, USA
8Missouri Baptist Hospital St. Louis, MO, USA
9Bowman Gray School of Medicine Winston-Salem, NC, USA
10Mt. Sinai School of Medicine New York, NY, USA
11Medical University of South Carolina Charleston, SC, USA

Correspondence to: Genitourinary Oncology Department of Medicine Section of Hematology/Oncology University of Chicago, Medical Center 5841 S. Maryland Ave. MC 2115 Chicago, IL 60637 1470 USA E-mail: njvogelz{at}mcis.bsd.uchicago.edu

Background: New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy.

Patients and methods: Thirty-five patients accrued to this multi-institutional phase II study of paclitaxel given as a 24-hour infusion at 250 mg/m2 every three weeks plus filgrastim (G-CSF) 300 meg subcutaneously days 3–18.

Results: There were three (9%) regressions of evaluable disease. The median survival was five months (95% confidence interval (95% CI): 1.9–9.6 months), the one-year survival rate was 14% and the two-year survival rate was 6%. Toxicity was tolerable with one death from pneumonia (without neutro-penia) on day 18 and a 23% rate of grade 4 granulocytopenia.

Conclusions: The level of activity seen with paclitaxel is similar to that seen in other CALGB trials of the single agents carboplatin, trimetrexate and 5-azacytidine. Future studies of of paclitaxel (at lower doses) in combination with synergistic agents could be considered.

mesothelioma, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Shukla, M. B. MacPherson, J. Hillegass, M. E. Ramos-Nino, V. Alexeeva, P. M. Vacek, J. P. Bond, H. I. Pass, C. Steele, and B. T. Mossman
Alterations in Gene Expression in Human Mesothelial Cells Correlate with Mineral Pathogenicity
Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 114 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green
The cancer and leukemia group B respiratory committee.
Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. V. Scagliotti, D.-M. Shin, H. L. Kindler, M. J. Vasconcelles, U. Keppler, C. Manegold, H. Burris, U. Gatzemeier, J. Blatter, J. T. Symanowski, et al.
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
J. Clin. Oncol., April 15, 2003; 21(8): 1556 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. A. Vorobiof, B. L. Rapoport, M. R. Chasen, R. P. Abratt, N. Cronje, L. Fourie, G. McMichael, and D. Hacking
Malignant pleural mesothelioma: a phase II trial with docetaxel
Ann. Onc., March 1, 2002; 13(3): 412 - 415.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. C. Steele, J. Shamash, M. T. Evans, N. H. Gower, M. D. Tischkowitz, and R. M. Rudd
Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol., December 1, 2000; 18(23): 3912 - 3917.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.